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Abstract Protein tyrosine phosphatases are not
considered to be metalloenzymes. Yet, they are
inhibited by zinc cations and metal and non-metal
oxyanions that are chemical analogues of phosphate,
e.g. vanadate. Metal inhibition is generally not recog-
nized as these enzymes are purified, supplied, and
assayed with buffers containing chelating and reduc-
ing agents. We screened a series of cations and anions
for their capacity to inhibit protein tyrosine phos-
phatase 1B and discuss the ensuing general issues with
inhibition constants reported in the scientific literature.
In contrast to zinc, which binds to the phosphocysteine
intermediate in the closed conformation of protein
tyrosine phosphatase 1B when the catalytic aspartate
has moved into the active site, other divalent cations
such as cadmium and copper may also bind to the
enzyme in the open conformation. Inhibition by both
anions and cations, conditions such as pH, the
presence of metal ligands such as glutathione, and
the existence of multiple conformational states of
protein tyrosine phosphatases in the reaction cycle
establish a complex pattern of inhibition of these
important regulatory enzymes with implications for
the physiology, pharmacology and toxicology of metal
ions.
Keywords Metal cations  Oxyanions  Inhibition 
Protein tyrosine phosphatase
Abbreviations
PTP Protein tyrosine phosphatase
GSH Glutathione
Introduction
Protein tyrosine phosphatases, a family of 107
enzymes in humans, are key regulators of cellular
phosphorylation signalling (Tonks 2013). To fulfil
this role, they are regulated themselves by a variety of
processes, e.g. covalent modification (phosphoryla-
tion, sumoylation), dimerization and a remarkable
redox chemistry involving the catalytic cysteine
residue. The enzymes work with two catalytic steps.
The phosphorylated substrate binds and transfers its
phosphate group to the catalytic cysteine to form a
phosphocysteine intermediate and the dephosphory-
lated susbstrate, the first product. In the second, rate-
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limiting step, the enzyme is dephosphorylated form-
ing phosphate, the second product. Inhibition of
protein tyrosine phosphatase 1B (PTP1B, PTPN1) by
zinc ions was noticed over 35 years ago (Brautigan
et al. 1981). It gains significance only now because
recent developments in the field of zinc biology
provide evidence for zinc ions serving functions as
cellular signalling ions in a range of concentrations
that is commensurate with the affinity of PTP1B and
for zinc (Haase and Maret 2003; Krezel and Maret
2008). Protein tyrosine phosphatases are thought to
be targets of these signalling zinc ions, adding yet
another layer of regulation to these important
enzymes. Zinc inhibition was found to be exquisitely
tight. A Ki value of 21 pM was determined for
receptor protein tyrosine phosphatase beta (RPTPb)
(Wilson et al. 2012). This affinity is close to that of
genuine metalloenzymes for zinc. Thus, in contrast to
zinc enzymes that are activated and employ their
metal for catalysis, other enzymes are inhibited by
zinc and zinc needs to be removed from the enzymes
for them to become active (Maret 2013). Such a mode
of action seems to have been generally overlooked as
active enzymes are prepared, supplied, and assayed
in the presence of chelating agents that bind the
inhibitory metal ion and hence mask the inhibition.
Specificity in the regulation of PTPs was noted when
zinc inhibition was observed in the closed confor-
mation of PTP1B (Bellomo et al. 2014). Protein
ligands for binding the inhibitory metal ion become
available only in the closed conformation. They are
thought to involve the carboxylate group of the
catalytic aspartate (Asp181) and the phosphate group
of the phosphocysteine intermediate. This mode of
inhibition is different from the redox modulation of
PTP activity, which occurs in the open protein
conformation when the catalytic cysteine is not
modified. In addition to metal oxyanions, non-metal
oxyanions such as nitrate bind to the catalytic site of
PTP1B (Kenny et al. 2014). In order to determine the
relative inhibition under the same conditions, we
screened the inhibitory capacity of a range of cations
and anions with a versatile and sensitive fluorimetric
enzymatic assay (Bellomo et al. 2014). The results
indicate that inhibition requires the binding of an
anion first to make possible the interaction of the
enzyme with a cation. Such an inhibition has wide
implications for the physiology, pharmacology, and
toxicology of metal ions.
Experimental procedures
Reagents
Molecular biology-grade HEPES, tris(2-car-
boxyethyl)phosphine hydrochloride (TCEP), nitrilo-
triacetic acid (NTA), zinc chloride (ZnCl2), copper
sulphate (CuSO4), cadmium chloride (CdCl2), lead
nitrate (Pb(NO3)2), ferric chloride (FeCl3), ammonium
iron(II) sulphate [(NH4)2Fe(SO4)26H2O], chromium
chloride (CrCl3), lanthanum chloride (LaCl3), lithium
chloride (LiCl), manganese chloride (MnCl2), nickel
chloride (NiCl2), silver nitrate (AgNO3), ammonium
tetrathiomolybdate [(NH4)2MoS4], sodium tungstate
(Na2WO4), potassium nitrate (KNO3), ammonium
molybdate [(NH4)2MoO4], sodium arsenate,
(Na2HAsO47H2O), sodium chromate (Na2CrO44H2-
O), boric acid (H3BO3), potassium hydrogen carbon-
ate (KHCO3), histidine, sodium hydroxide, and Triton
X-100 were from Sigma-Aldrich; ammonium hepta-
molybdate [(NH4)6Mo7O24] from BDH Laboratory
Supplies, Poole, UK; 6,8-difluoro-4-methylumbellif-
eryl phosphate (DiFMUP) and 6,8-difluoro-7-hy-
droxy-4-methylcoumarin (DiFMU) were from
Invitrogen. Recombinant human PTP1B, residues
1–299, was fromMillipore, supplied in 50 mMHepes,
pH 7.2, 1 mM dithiothreitol (DTT), 1 mM ethylene-
diaminetetraacetic acid (EDTA), and 0.05% (v/v) NP-
40. Chromium (III) histidinate was used because it is
the least kinetically inert complex. To prepare
chromium (III) histidinate, chromium (III) chloride
(20mmoles) and histidine (60mmoles) were dissolved
in 150 mL water and heated to 80 C for 15 min,
sodium hydroxide (50 mmoles) in 50 mL water was
added within four minutes. The blood red complex
was used for the experiments.
Metal cation and oxyanion inhibition assay
Enzymatic activity of PTP1B (2.5 nM final concen-
tration) was assayed fluorimetrically at 25 C in a
buffer containing 50 mM Hepes/Na?, pH 7.4, 1 mM
NTA, 0.01% (v/v) Triton X-100, freshly prepared
0.1 mM TCEP, and with different concentrations of
metal cations or oxyanions. The reaction was initiated
by adding the fluorigenic phosphatase substrate
DiFMUP. Assays were performed in triplicates in a
total volume of 100 ll in 96-well black optical bottom
plates (Greiner Bio-One Ltd, Stonehouse, UK).
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Product formation (hydrolysis of DiFMUP to DiFMU)
was monitored at 460 nm emission and 360 nm
excitation with a fluorescence plate reader (Synergy
HT, BioTek, Winooski, VT). Initial rates were deter-
mined from the linear portion of the progress curves.
Fluorescence intensity was converted to molar con-
centrations from measurements with a standard of a
DiFMUP–DiFMU mixture.
Determination of total and free Cu2?, Cd2?
and Zn2? and their inhibition
In order to determine inhibition constants of the metal
cations on the activity of PTP1B, we usedMaxchelator
(Environmental Research Software, Hallowell, ME)
(Bers et al. 2010) to calculate the concentration of free
Cu2?, Cd2? and Zn21 in the buffer (Table 1). The
concentrations of EDTA and DDT in the diluted
commercial PTP1B used in the assay were incorpo-
rated into the calculations for free metal ion concen-
trations using Maxchelator. NTA (1 mM) in the pH-
buffer solutions was used to buffer copper, cadmium
and zinc ions. When using 1 mM GSH instead of
1 mM NTA in the assay, the calculations of free zinc
ion concentrations were provided by Professor Wojtek
Bal (Polish Academy of Science, Warsaw) (Table 2).
The metal buffered solutions were freshly prepared
and equilibrated for 15 min before the assay was
started by adding enzyme. The reaction was monitored
under initial velocity conditions. Inhibition constants
(apparent Ki values) were obtained from fitting semi-
logarithmic plots with non-linear regression curves
(Sigma plot).
Zinc analysis by ICP-MS
One of the major issues in determining PTP1B activity
is the contamination of zinc in the experimental
solutions and buffers. Zinc is a ubiquitous contaminant
of laboratory chemicals. In order to monitor zinc
levels, total zinc concentrations in solutions and
buffers were measured using inductively coupled







1 1.18 9 10-14 1 2.05 9 10-11 10 2.66 9 10-11
5 5.95 9 10-14 5 1.03 9 10-10 50 1.39 9 10-10
10 1.19 9 10-13 30 3.30 9 10-10 200 6.58 9 10-10
30 3.66 9 10-13 50 1.08 9 10-9 300 1.13 9 10-9
50 6.23 9 10-13 200 5.12 9 10-9 700 6.15 9 10-9
100 1.31 9 10-12 350 1.10 9 10-8 800 1.05 9 10-8
200 2.96 9 10-12 600 3.07 9 10-8 900 2.37 9 10-8
300 5.07 9 10-12 800 8.19 9 10-8 950 5.01 9 10-8
500 1.18 9 10-11 900 1.84 9 10-7 970 8.52 9 10-8
980 9.61 9 10-7 980 1.29 9 10-7
990 2.57 9 10-7
50 mM Hepes, pH 7.4, 1 mM NTA, 0.1 mM TCEP and 0.01% (v/v) Triton X-100. Free metal ion concentrations were calculated
using the program MaxChelator
Table 2 Free zinc (II) ion concentrations in solutions metal-
buffered with glutathione (GSH)
[Zn2?]total (lM) [Zn
2?]free (M)
1 5.88 9 10-9
3 1.76 9 10-8
7 4.19 9 10-8
10 6.04 9 10-8
30 1.92 9 10-7
70 5.02 9 10-7
100 7.84 9 10-7
300 4.57 9 10-6
700 4.88 9 10-5




plasma mass spectrometry (ICP-MS, Perkin Elmer
Life Science, model Elan 610 DRC plus). Samples
were prepared in 5% (v/v) HNO3-washed polypropy-
lene tubes (Elkay, Basingstoke, UK).
Results
Effect of metal cations on PTP1B activity
We investigated a total of 20 metal ions (12 cations
and 8 oxyanions) with regard to their capacity to
modulate the activity of PTP1B (Table 3). Metal
cations generally inhibited more strongly than oxyan-
ions. Copper(II), cadmium(II), zinc(II), lead(II) and
silver(I) at concentration between 5 and 50 lM,
respectively, inhibited between 90 and 99%. Man-
ganese(II) and nickel(II) ions did not inhibit PTP1B at
these concentrations. We also investigated the effect
of the charge of the cation by employing trivalent
(chromium) and monovalent (lithium) cations. They
also did not inhibit significantly the activity of
PTP1B, confirming previous observations regarding
chromium(III) (Hong et al. 2005). Higher concentra-
tion of some metal cations such as lanthanum(III),
iron(II,III), and lead(II) between 100 lM and 1 mM
activated PTP1B.
Femtomolar and nanomolar concentrations
of Cu2?, Cd2? and Zn2? inhibit PTP1B
In addition to Zn21, we determined the inhibition for
Cu2? and Cd2?, two cations with high affinity to
ligands according to the Irving-Williams series. Based
on free Cu2?, Cd2? and Zn21 concentrations and
fitting the data to a non-linear regression curve, we
obtained inhibition constants of 600 fM, 7.3 nM and
2.4 nM, respectively (Figs. 1a, b and 2a). In contrast
Table 3 Effects of metal cations and oxoanions on PTP1B activity






Zinc (Zn2?) I 10 lM 95
Cadmium (Cd2?) I 10 lM 91
Copper (Cu2?) I 5 lM 99
Lead (Pb2?) I/A 5 lM/1 mM 96/87
Silver (Ag?) I 50 lM 92
Iron (Fe2?) I/A 5 lM/500 lM 77/74
Iron (Fe3?) I/A 10 lM/500 lM 71/68
Chromium (Cr3?) NSa – –
Lanthanum (La3?) I/A 1 lM/100 lM 63/15
Lithium (Li?) NSa – –
Manganese (Mn2?) NSa – –




I 100 lM 97
Tungstate (WO4
2-) I 500 lM 62
Nitrate (NO3




I 100 lM 88
Arsenate (AsO4
3-) I 500 lM 66
Chromate (CrO4
2-) I 500 lM 81
Borate (BO3
3-) NSa – –
Carbonate (CO3
2-) NSa – –
a NS no significant effect. n = 3
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to Cu2? and Cd2?, Zn21 did not inhibit PTP activity
completely under these conditions (Fig. 2a).
Effect of Zn2? buffered with glutathione
on PTP1B activity
Glutathione (GSH) serves as a redox and metal buffer
in cells. When using 1 mM GSH instead of 1 mM
NTA and 0.1 mM TCEP in the assay solution, Zn2?
inhibited the enzyme completely with an inhibition
constant of 200 nM (Fig. 2b).
Effect of oxyanions on PTP1B activity: inhibition
constants of vanadate, molybdate, tungstate,
arsenate, and nitrate
Some metal oxyanions are analogues of phosphate,
which is the hydrolytic product of the PTP reaction.
Phosphate is a competitive inhibitor of PTP1B with a
Ki value of 17 mM (Zhang and Zhang 1998). Other
oxyanions with structural similarities to phosphate
also inhibit PTPs, e.g. vanadate, molybdate, tungstate
and arsenate. Among them, vanadate seems to be the
strongest inhibitor of PTP1B with a Ki value of
0.38 lM (Huyer et al. 1997). Among the metal
oxyanions we investigated, tetrathiomolybdate and
heptamolybdate showed the strongest inhibition (97
and 88% respectively) at a concentration of 100 lM.
Tungstate, arsenate and chromate inhibited PTP1B
activity 62–81% at higher concentrations between
500 lM and 100 mM (Table 3). Among the non-
metal oxyanions tested, nitrate inhibited a bit weaker
than phosphate, while borate and carbonate did not
inhibit significantly.
Under identical assay conditions, the apparent Ki
(IC50) values are 1.5 lM (vanadate), 9 lM (hepta-
molybdate), 200 lM (molybdate) (data collected by
Ms. Sherry Sachdeva), 210 lM (tungstate), 200 lM
(arsenate), and 54 mM (nitrate) (Fig. 3a–e). The
different inhibition constants may reflect different
ionization states of the anion at the pH of investiga-
tion, in the case of vanadate the propensity to form a
covalent intermediate analogous to the phospho-
intermediate in contrast to the other anions that form
Michaelis-like complexes, and last but not least
geometric factors, such as in the case of nitrate, which
has a planar geometry.
Discussion
Inhibition by oxyanions
In an overview of the molecular and ionic mimicry of
metal ions, it was summarized that arsenate (As(V))
and vanadate (V(V)) are structurally similar to
endogenous phosphate (P(V)) and mono-anions due
to partial ionization while chromate (Cr(VI)) and
molybdate (Mo(VI)) are structurally similar to
endogenous sulphate (S(VI)) are fully ionized and
Fig. 1 Cu2? and Cd2? inhibition of PTP1B. The enzyme was
assayed with increasing concentrations of free copper(II) ions
(a) and cadmium(II) ions (b) as calculated using Maxchelator
(Table 1) in a buffer containing 50 mM Hepes, 1 mM NTA,
0.1 mM TCEP and 0.01% (v/v) Triton X-100, pH 7.4.
Experiments were performed in triplicate for each metal ion.
The enzyme was added to the buffer containing the metal
cations and 3 lM DiFMUP
Biometals
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hence di-anions (Clarkson 1993). Metal oxyanions
that are analogues of phosphate inhibit PTP1B.
Vanadate is a transition state inhibitor forming a
covalent intermediate with the active site cysteine of
the enzyme (Brandao et al. 2010; McLauchlan et al.
2015). Molybdate and tungstate are product inhibitors
and do not form covalent intermediates. Oxyanions of
non-metals also bind at the active site and inhibit the
enzyme, i.e. sulphate and sulphonates such as Hepes
buffer, arsenate, and nitrate. The protonation state of
the anion, i.e. the pKa value of its conjugate acid, is
important for inhibition. For example, in the case of
phosphate, the dianion binds. Hydrogenphosphate
(HPO4
2-) interacts with the guanidinium group of
Arg221 of PTP1B in its closed conformation. For
phosphoric acid the pKa values are 2.0, 5.7 and 11.7
while they are 3.8, 7.8, and 13 for H3VO4 (25 C,
I = 0.5). The stereochemistry is also important. In a
crystal structure of PTP1B in the presence of nitrate,
nitrate is bound in the active site and 50% of the
protein molecules are in the closed conformation
(Kenny et al. 2014). Inhibition constants were not
reported, however. We show that nitrate, which is a
monoanion and has a planar geometry, indeed inhibits
PTP1B but rather weakly with an IC50 value of
54 mM. The inhibition is expected to be stronger in
the closed conformation of the enzyme because
additional interactions of nitrate with the side chains
of Asp181 and Arg221 were observed (Kenny et al.
2014).
The inhibition constants for molybdate and tung-
state are similar. There is no significant difference
between the pKa values (20 C, I = 0.1) of molybdic
acid (pKa1 = 4.2; pKa2 = 8.2) and tungstic acid
(pKa1 = 3.5; pKa2 = 8.1) (Smith and Martell 1976).
However, the inhibition of PTP1B by heptamolybdate
is about one order of magnitude stronger. An inves-
tigation of Keggin compounds that hydrolyse to the
mononuclear anions in water also shows that molyb-
date and tungstate inhibit with virtually the same IC50
values (21 and 25 lM respectively) at pH 7.5 (Heo
et al. 2002). Yet, there are structural differences. The
crystal structure of PTP1B in the presence of phos-
phomolybdate shows the MoO3 moiety (derived from
phosphomolybdate by hydrolysis) binding at the
active site. The molybdenum atom is six-coordinate
with three oxo-ligands in MoO3, two apical water
molecules and an S atom from the catalytic cysteine
residue, while in the complex with tungstate the WO4
moiety is five-coordinate with four oxo-ligands and an
interaction with the S atom of the catalytic cysteine. In
contrast to the molybdate complex, the side chain of
Gln262 of PTP1B interacts with one of the oxo-
ligands in the tungstate complex (Heo et al. 2002).
Unlike in the complex with vanadate the protein is in
the open conformation and there is no interaction with
the side chain of Arg221. The crystal structure of
PTP1B with tungstate shows the tetrahedral anion
log[Zn]











Fig. 2 Zn2? inhibition of PTP1B in the absence and presence
of glutathione. The enzyme was assayed with increasing
concentrations of free zinc(II) ions as calculated using
Maxchelator (Table 1) in a buffer containing 50 mM Hepes,
1 mM NTA, 0.1 mM TCEP and 0.01% (v/v) Triton X-100, pH
7.4 (A) or in a buffer containing 50 mM Hepes, pH 7.4, 1 mM
GSH and 0.01% (v/v) Triton X-100 (B). The enzyme was
assayed with increasing concentrations of free zinc (II) ions
according to calculations provided by Professor Wojciech Bal
(Polish Academy of Science, Warsaw) (Table 2). Experiments
were performed in triplicate. Enzyme was added to the buffer
containing zinc(II) ions and 3 lM DiFMUP
Biometals
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Fig. 3 Oxyanions inhibit PTP1B. The enzyme was assayed
with increasing concentrations of vanadate (a), tungstate (b),
heptamolybdate (c), arsenate (d) and nitrate (e) in a buffer
containing 50 mM Hepes, 1 mM NTA, 0.1 mM TCEP and
0.01% (v/v) Triton X-100, pH 7.4. Experiments were performed
in triplicate for each oxyanion. The enzyme was added to the
buffer containing the oxyanions and 3 lM DiFMUP
Biometals
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bound only to NH groups of the peptide backbone in
the open conformation of the protein (Barford et al.
1998). However, the Yersinia PTP complex with
tungstate is in the closed conformation with additional
interactions with the active site Asp, Arg, and Gln
residues (Fauman et al. 1996). The crystal structure of
bovine low molecular weight PTP with molybdate
reveals that the molybdenum atom is coordinated with
six ligands: three oxo-ligands, two apical water
molecules and an S atom of the catalytic cysteine
residue (Zhang et al. 1997). For this enzyme, the
authors report inhibition constants of 9 and 210 lM
for molybdate and tungstate, respectively. Thus, a
major issue remains whether or not measured inhibi-
tion constants relate to the open or to the closed
conformation of the enzyme. Additional stabilization
in the closed conformation suggests tighter binding. In
order to further elucidate the inhibition properties we
investigated the third member of this group, namely
chromate. It is a weaker inhibitor than molybdate with
an IC50 value of about 400 lM. Chromic acid is a
much stronger acid than either molybdic acid or
tungstic acid (pKa = -0.98 for H2CrO4). Moreover,
chromate is a larger oxyanion than molybdate
(Bridges and Zalups 2010).
Arsenate inhibits PTP1B with a Ki of 150 lM (pH
7.0) (Zhang and Zhang 1998). Under our experimental
conditions, arsenate inhibits PTP1B with similar
strength (IC50 & 200 lM, pH 7.4). The pKa2 of
arsenate is 7.03–7.10 and thus between those of
phosphate and vanadate. A crystal structure of PTP1B
with arsenate has not been reported. However, several
crystal structures of arsenate reductase have been
solved and shown that the structure of this enzyme is
related to the PTP family (Hu et al. 2015). Remark-
ably, the protein phosphatase CD45 belonging to the
PTP superfamily reduces arsenate. A number of
eukaryotic enzymes that function as arsenate reduc-
tases are homologues of the catalytic domain of the
human Cdc25 phosphatase, suggesting that Cdc25 has
the potential to reduce arsenate to the more toxic
arsenite. It may provide a framework to identify other
human PTPs containing active sites that might moon-
light as arsenate reductases (Bhattacharjee et al. 2010).
Other oxyanions like borate show no significant
effect on PTP1B activity. Borate is a monoanion, such
as nitrate and hydrogencarbonate, with a pKa value of
9.23 for the transition B(OH)3 to H2BO
-. Hence it is
expected to interact weakly with PTPs.
Inhibition by cations
Inhibition of PTP1B by zinc (II) ions has been known
for a long time (Brautigan et al. 1981). However, it was
not known where zinc binds, inhibition constants were
not obtained, and the inhibition was not discussed in the
context of the available free zinc ion concentrations in
the cell. It is now known that fluctuating zinc ion
concentrations in the cell have signalling functions and
a significant body of work indicates an effect on
phosphorylation signalling (Maret 2009; Bellomo et al.
2016). The inhibition is much stronger than originally
reported (21 pM for RPTPb/PTPRB (Wilson et al.
2012) and 5–15 nM for PTP1B (Haase andMaret 2003;
Krezel and Maret 2008). The strong binding is thought
to be due to zinc binding in the closed conformation of
the enzyme when additional interactions with the
phosphocysteinyl residue and the catalytic aspartate
are possible (Bellomo et al. 2014). The investigations
established zinc ions as a physiological modulator of
protein tyrosine phosphatases with wide implications
for signal transduction (Bellomo et al. 2016). In the
present investigation, we addressed the role of other
metal ions, which unlike calcium and zinc change
concentrations only under pathological conditions and
under environmental (nutritional, pharmacological,
toxicological) exposure. Cellular metal ions are buf-
fered and the free metal ion concentrations depend on
the buffering capacity. Thus, cellular metal ion con-
centrations are not just influenced by the metal ion
concentrations available extracellularly but also by any
factor that changes the buffering capacity of the cell.
Whether reactions are physiologically significant
depends on this buffering capacity. Outside this range
of the cellular metal ion buffering capacity, metals have
pharmacological or toxicological actions. As with
anions charge is perhaps the most important factor for
divalent metal ions inhibiting PTPs. With the exception
of thiophilic cations such a silver(I) ions, mono- and
trivalent metal ions inhibit PTP1B relatively weakly.
Since the strength of binding of divalent cations
generally follows the Irving-Williams series, we
focused on two other strongly binding divalent cations
in addition to zinc, namely cadmium and copper.
Cadmium
Cd2? binds as strong as Zn2?, but in contrast to zinc
the interaction is complete without incubating the
Biometals
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protein with the metal ion, suggesting that cadmium,
which has a higher affinity to sulphur than zinc,
inhibits the enzyme in the open conformation. We
noted that zinc in the presence of glutathione also
gives complete inhibition. Glutathione (GSH) is both a
reducing and a complexing agent and therefore NTA
and TCEP are not required when assaying PTP1B.
Glutathione forms complexes with zinc, including
ternary complexes with ligands such as histidine
(Krezel et al. 2003). Hence glutathione and zinc may
bind together in the open conformation of the enzyme.
Copper
Cu2? is the most potent inhibitor of PTP1B with an
IC50 value of 0.6 pM. As copper (II) ions oxidize the
thiol of cysteine in the presence of oxygen, they are
irreversible inhibitors. Thus, the highly potent Cu2?
inactivation of the PTPT VHR was discussed as a
consequence of the cupric ions oxidizing the active-
site cysteine (Zhu et al. 2013). In the cell, copper is
mostly in the form of copper(I) and therefore it is
important to investigate copper(I) complexes. They
inhibit PTPs more weakly (Wang et al. 2010, 2011).
Exposure of cells to copper(II) complexes results in
inhibition of PTPs. The proposed mechanism of
inhibition of PTP1B by the copper(II) complex (bis-
thiosemicarbazonato copper complexes) involves the
complex entering the cell, Cu2? reduction to Cu? in
the cell, and finally inhibition of PTP1B activity,
leading, for example, to sustained phosphorylation and
activation of the epidermal growth factor receptor
(Price et al. 2009).
Inhibition of PTPs by metal ions and metal ion
complexes was investigated extensively by others
(Table 4). However, our investigations demonstrate
that interpretation and comparison of data is hampered
by many factors. In addition to redox, metal ion, and
pH control in assays, interactions between cations and
anions need to be considered. A synergism or antag-
onism would make the binding constant of one species
dependent on that of the other. Thus, anions and
cations of the same element in different oxidation may
bind, i.e. the vanadate (V(V)) anion and the oxyvana-
dium (V(IV)) cation or Cr(III)/Cr(VI)(chromate). Zinc
concentrations need to be considered and controlled
when testing other anions or cations because zinc is a
common contaminant of many reagents at concentra-
tions causing strong inhibition of PTPs. The inhibition
constants need to be interpreted in terms of the species
of the inhibitor and the form of the enzyme inhibited.
For example, arsenate binds at the anion binding site in
the closed conformation of the enzyme whereas
As(III) compounds such as the arsenicals monomethy-
larsonous acid and dimethylarsinous acid have high
affinity to the sulphhydryl groups of PTP1B and lead
to irreversible inhibition (Kanwal et al. 2012).
Depending on the affinity of the cation for sulphur,
the metal ion can bind to the protein in the open
conformation and/or the closed conformation. If it
binds to both forms, the measured inhibition constant
will be the product of two different molecular
Table 4 Metal ions/metal ion complexes inhibiting human protein tyrosine phosphatases
Metal ion/metal ion complex PTP1B SHP-1 SHP-2 TCPTP Reference
Zinc 3–17 nM 93 nM 1–2 lM 200 nM Bellomo et al. (2014); Haase and Maret
(2005); Haase and Maret (2003)
Copper 0.14 lM 0.18 lM – 0.15 lM Zhu et al. (2013)
Vanadate 0.38–33 lM 13 lM – – Huyer et al. (1997); Heo et al. (2002)
Tungstate 20–210 lM – – – Zhang et al. (1997); Heo et al. (2002)
Molybdate 9–3 lM 10–20 lM – – Zhang et al. (1997); Heo et al. (2002)
Arsenate 4.3 mM – – – Zhang and Zhang (1998)
Dinuclear copper complex 0.15 lM 0.23 lM [100 lM 1.81 lM Ma et al. (2011)
Mononuclear iron dicitrate – 250 lM – – Gomez et al. (2010)
Vanadium complex 0.03–1 lM – – – Lu and Zhu (2014)
Bis-(maltolato)oxovanadium(IV) 0.86 lM – – – Li et al. (2008)
Sodium stibogluconate 100 lg/ml 10 lg/ml 100 lg/ml – Lu and Zhu (2011)
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constants. Once the binding constants are obtained
under defined conditions, they need to be interpreted
in terms of the metal ion availability in the cell to
assign physiological, pharmacological, or toxicologi-
cal importance. Such a consideration strengthens or
weakens the argument for a cation or an anion being
important for the inhibition of the enzyme(s) in vivo.
Strictly, we show these effects for PTP1B only but the
inhibition observed for many other PTPs (Table 4)
make our results more generally applicable.
Conclusions
We conclude that a variety of metal cations and metal
oxyanions are rather potent PTP1B inhibitors while
non-metal oxyanions are generally weak inhibitors.
Among cations, Cu2? ions inhibit PTP1B activity at
femtomolar concentrations while Cd2? and Zn2? ions
inhibit at nanomolar concentrations. Glutathione
affects the mode of zinc inhibition of PTP1B activity.
The inhibition is thought to occur in the enzyme in the
open conformation (for highly thiophilic metal ions)
and/or in the closed conformation of the enzyme (for
less thiophilic metal ions). Investigations at varying
pH values, lack of knowledge of the type of inhibition
and control of anions and cations make it difficult or
nearly impossible to compare inhibition data of PTPs
in the literature. PTP1B has been and continues to be a
major therapeutic target for inhibition by low molec-
ular weight compounds and drug candidates (Hene-
berg 2009) because of its role in many important
physiological and pathophysiological processes (dia-
betes, cancer, neurodegeneration). Understanding the
structural basis of the interactions of PTP1B with
metal ions/metal ion complexes and possible syner-
gism between cations and anions will be important for
future design of novel therapeutic agents and for
addressing the molecular toxicology of metal ions and
the cumulative risks associated with exposures.
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